HEОбмен на изследователи2025–2029

NEUROHEALTH · Transitioning Psychotropic Alkaloids From Plants And Mushrooms To Neuroprotective Agents: Incorporating Computational Tools For The Development Of Novel Therapeutics

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2025-10-01 → 2029-09-30
Финансиране от ЕС
1 803 600 €
Участници
10
Схема
HORIZON-TMA-MSCA-SE

Линиите свързват координатора с партньорите.

Накратко на български

Алкалоидите от психотропни растения и гъби се анализират с компютърни инструменти, за да се открият вещества за защита на мозъка. Това помага за разработването на нови терапии при заболявания като Алцхаймер и Паркинсон, с цел подобряване на когнитивното здраве.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

The NeuroHEALTH project aims to address the growing challenge of neurodegenerative diseases, such as Alzheimer's and Parkinson's, which affect millions worldwide and impose significant social and economic burdens. The project will harness the potential of neglected natural products (NPs), like alkaloids, from psychotropic plants and mushrooms that till recently had regulatory constrains. The integration of state of the art phytochemical analysis, with advanced computational tools will accelerate the discovery of novel NPs. In vitro and in vivo testing assays including zebrafish models will evaluate the safety and efficacy to reveal compounds of interest, that can enhance cognitive health and improve quality of life. Bioactive extracts and NPs will be scaled up and formulated in combination with a market analysis, sustainability and intellectual properties assessment will ensure that findings are relevant and applicable. Through strategic secondments and staff exchanges among academic and industry partners, NeuroHEALTH will foster interdisciplinary collaboration, enhancing knowledge transfer and innovation. Workshops, conferences, and outreach activities will engage diverse stakeholders, including professionals, policymakers, and the general public, promoting awareness of the project's findings and their implications for health care. By bridging the gap between traditional knowledge and modern science, NeuroHEALTH aims to deliver impactful solutions for neurodegenerative diseases, ultimately contributing to healthier aging populations. This timely initiative not only addresses urgent societal needs but also positions Europe at the forefront of innovative research in natural product-based therapeutics.

Оригинален текст от CORDIS (на английски).

Участници

  • ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON · ATHINAКоординаторГърция
  • EDEX - EDUCATIONAL EXCELLENCE CORPORATION LIMITED · NicosiaКипър
  • ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS · THERMI THESSALONIKIГърция
  • FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA · Armilla GranadaИспания
  • Galen-N · SofiaБългария
  • NIKOLAOS A. FIKIORIS KAI SIA ETAIREIA PERIORISMENIS EFTHYNIS · ATHENSГърция
  • NOVAMECHANICS LIMITED · NicosiaКипър
  • PARALAB-EQUIPAMENTOS INDUSTRIAIS E DE LABORATORIO S.A. · GondomarПортугалия
  • UNIVERSITE PARIS CITE · ParisФранция
  • UNIWERSYTET MEDYCZNY W LUBLINIE · LublinПолша

Връзки

Данни: CORDIS, © Европейски съюз